James E Lyons

Address:

5135 Rockwood Pkwy NW, Washington, DC 20016

Phone:

2027256831

VIN:

1GYEE637670146376

Make:

CADILLAC

Model:

SRX

Year:

2007

US Patent:

20220273608, Sep 1, 2022

Filed:

May 16, 2022

Appl. No.:

17/745556

Inventors:

Joseph Stains - Laurel MD, US
Christopher Ward - Baltimore MD, US
James Lyons - York PA, US

Assignee:

University of Maryland, Baltimore - Baltimore MD

International Classification:

A61K 31/337
C07K 16/22
A61K 31/165
A61P 19/08
A61K 39/395

Abstract:

Provided herein are methods for treating a bone-related disorder in a subject. At least one of a microtubule altering drug, for example, a microtubule disrupting drug or a microtubule stabilizing drug, a TRPV4 agonist or a NOX2 activator is administered to the subject. Also provided are related methods for treating a bone-related disorder in the subject by further administering at least one of an anti-sclerostin agent, a parathyroid hormone agonist, a bisphosphonate, an estrogen mimic, or a selective estrogen receptor modulator with the at least one of a microtubule altering drug, a TRPV4 agonist or a NOX2 activator.

US Patent:

20190351055, Nov 21, 2019

Filed:

Nov 16, 2017

Appl. No.:

16/461555

Inventors:

- Baltimore MD, US
Christopher Ward - Baltimore MD, US
James Lyons - York PA, US

Assignee:

University of Baltimore, Maryland - Baltimore MD

International Classification:

A61K 39/395
A61K 31/337
A61K 31/495
A61K 31/496
A61K 31/365
A61P 19/08

Abstract:

Provided herein are methods for treating a bone-related disorder in a subject. At least one of a microtubule altering drug, for example, a microtubule disrupting drug or a microtubule stabilizing drug, a TRPV4 agonist or a NOX2 activator is administered to the subject. Also provided are related methods for treating a bone-related disorder in the subject, by further administering at least one of an anti-sclerostin agent, a parathyroid hormone agonist, a bisphosphonate, an estrogen mimic, or a selective estrogen receptor modulator is further administered to the subject with the at least one of a microtubule altering drug, a TRPV4 agonist or a NOX2 activator.